These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 31326611)
1. Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Jaimes-Albornoz D; Mannone L; Nguyen-Quoc S; Chalandon Y; Chevallier P; Mohty M; Meunier M; Robin M; Ledoux MP; Guillerm G; Bay JO; Poiré X; Maillard N; Leclerc M; Daguindau E; Beguin Y; Rubio MT; Gyan E Biol Blood Marrow Transplant; 2019 Dec; 25(12):2366-2374. PubMed ID: 31326611 [TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985 [TBL] [Abstract][Full Text] [Related]
3. [Analysis of the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome with blastomycosis and survival comparison of different subtypes after the WHO 2022 reclassification]. Wang H; Ma RZ; Pang AM; Yang DL; Chen X; Zhang RL; Wei JL; Ma QL; Zhai WH; He Y; Jiang EL; Han MZ; Feng SZ Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):445-452. PubMed ID: 38964918 [No Abstract] [Full Text] [Related]
4. Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation. Alam N; Atenafu EG; Kuruvilla J; Uhm J; Lipton JH; Messner HA; Kim DH; Seftel M; Gupta V Bone Marrow Transplant; 2015 Sep; 50(9):1180-6. PubMed ID: 26121109 [TBL] [Abstract][Full Text] [Related]
5. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). Candoni A; Rambaldi A; Fanin R; Velardi A; Arcese W; Ciceri F; Lazzarotto D; Lussana F; Olivieri J; Grillo G; Parma M; Bruno B; Sora F; Bernasconi P; Saccardi R; Foà R; Sessa M; Bresciani P; Giglio F; Picardi A; Busca A; Sica S; Perruccio K; Zucchetti E; Diral E; Iori AP; Colombo AA; Tringali S; Santarone S; Irrera G; Mancini S; Zallio F; Malagola M; Albano F; Carella AM; Olivieri A; Tecchio C; Dominietto A; Vacca A; Sorasio R; Orciuolo E; Risitano AM; Leotta S; Cortelezzi A; Mammoliti S; Oldani E; Bonifazi F; Biol Blood Marrow Transplant; 2019 Dec; 25(12):2388-2397. PubMed ID: 31400502 [TBL] [Abstract][Full Text] [Related]
6. [The clinical analysis of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings in 95 patients with myelodysplastic syndrome]. Zhao T; Huang X; Liu D; Wang J; Zhang X; Wang Y; Han W; Chen H; Chen Y; Wang F; Liu K; Xu L Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):89-93. PubMed ID: 24767157 [TBL] [Abstract][Full Text] [Related]
7. Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome. Itonaga H; Ishiyama K; Aoki K; Aoki J; Ishikawa T; Uchida N; Ohashi K; Ueda Y; Fukuda T; Sakura T; Ohno Y; Iwato K; Okumura H; Kondo T; Ichinohe T; Takanashi M; Atsuta Y; Miyazaki Y Ann Hematol; 2019 Jun; 98(6):1367-1381. PubMed ID: 30854574 [TBL] [Abstract][Full Text] [Related]
8. Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. Yam C; Crisalli L; Luger SM; Loren AW; Hexner EO; Frey NV; Mangan JK; Gao A; Stadtmauer EA; Porter DL; Reshef R Am J Hematol; 2016 Sep; 91(9):883-7. PubMed ID: 27197602 [TBL] [Abstract][Full Text] [Related]
9. HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. Robin M; Porcher R; Ruggeri A; Blaise D; Wolschke C; Koster L; Angelucci E; Stölzel F; Potter V; Yakoub-Agha I; Koc Y; Ciceri F; Finke J; Labussière-Wallet H; Cascon MJP; Verbeek M; Rambaldi A; Cornelissen JJ; Chevallier P; Radia R; Nagler A; Fegueux N; Gluckman E; de Witte T; Kröger N Biol Blood Marrow Transplant; 2019 Jan; 25(1):114-120. PubMed ID: 30172776 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO). Basquiera AL; Rivas MM; Remaggi G; Klein G; Milovic V; Foncuberta MC; Saba S; Milone JH; Arbelbide J; Jaimovich G; Rolón JM; Kusminsky G; García JJ; Prates MV Hematology; 2016 Apr; 21(3):162-9. PubMed ID: 26147089 [TBL] [Abstract][Full Text] [Related]
11. T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors. Mariotti J; Devillier R; Bramanti S; Sarina B; Furst S; Granata A; Faucher C; Harbi S; Morabito L; Chabannon C; Carlo-Stella C; Bouabdallah R; Santoro A; Blaise D; Castagna L Biol Blood Marrow Transplant; 2018 Mar; 24(3):627-632. PubMed ID: 29197681 [TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome. Hsu C; Lin MT; Tang JL; Tien HF; Wang CH; Chen YC J Formos Med Assoc; 1999 Mar; 98(3):157-64. PubMed ID: 10365533 [TBL] [Abstract][Full Text] [Related]
13. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. Sengsayadeth S; Gatwood KS; Boumendil A; Labopin M; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gilleece MH; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A Blood Adv; 2018 Aug; 2(16):2127-2135. PubMed ID: 30143527 [TBL] [Abstract][Full Text] [Related]
14. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes. Dalle JH; Balduzzi A; Bader P; Lankester A; Yaniv I; Wachowiak J; Pieczonka A; Bierings M; Yesilipek A; Sedlaçek P; Ifversen M; Sufliarska S; Toporski J; Glogova E; Poetschger U; Peters C Biol Blood Marrow Transplant; 2018 Sep; 24(9):1848-1855. PubMed ID: 29772352 [TBL] [Abstract][Full Text] [Related]
15. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Woodard P; Barfield R; Hale G; Horwitz E; Leung W; Ribeiro R; Rubnitz J; Srivistava DK; Tong X; Yusuf U; Raimondi S; Pui CH; Handgretinger R; Cunningham JM Pediatr Blood Cancer; 2006 Dec; 47(7):931-5. PubMed ID: 16155933 [TBL] [Abstract][Full Text] [Related]
16. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982 [TBL] [Abstract][Full Text] [Related]
17. Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Tazoe K; Harada N; Makuuchi Y; Kuno M; Takakuwa T; Okamura H; Hirose A; Nakamae M; Nishimoto M; Nakashima Y; Koh H; Hino M; Nakamae H Ann Hematol; 2024 Jun; 103(6):2059-2072. PubMed ID: 38662207 [TBL] [Abstract][Full Text] [Related]
18. Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation. Zhu P; Lai X; Liu L; Shi J; Yu J; Zhao Y; Yang L; Yang T; Zheng W; Sun J; Wu W; Zhao Y; Cai Z; Huang H; Luo Y J Transl Med; 2024 Mar; 22(1):275. PubMed ID: 38481248 [TBL] [Abstract][Full Text] [Related]